A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

ClinicalTrials.gov ID: NCT07029828

Public ClinicalTrials.gov record NCT07029828. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss. This study is seeking participants who have: * previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031). * at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031). * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial. Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial. The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home. The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.

Study identification

NCT ID: NCT07029828
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Pfizer; Industry
Enrollment: 140 participants

Conditions and interventions

Conditions

Severe Alopecia Areata

Interventions

Ritlecitinib higher dose Drug
Ritlecitinib lower dose Drug

Drug

Eligibility (public fields only)

Age range: 6 Years to 14 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 10, 2025 (Actual)
Primary completion: Jun 26, 2030 (Estimated)
Completion: Jun 26, 2030 (Estimated)
Last update posted: Oct 15, 2026

2025 – 2030

United States locations

U.S. sites: 23
U.S. states: 15
U.S. cities: 20

Facility	City	State	ZIP	Site status
University of California~ Irvine	Irvine	California	92697	Recruiting
Southern California Clinical Research	Santa Ana	California	92701	Recruiting
Children's Hospital Colorado	Aurora	Colorado	80045	Recruiting
Children's National Hospital	Washington D.C.	District of Columbia	20010	Recruiting
Pediatric Skin Research	Miami	Florida	33156	Recruiting
Endeavor Health Clinical Operations	Skokie	Illinois	60077	Recruiting
Dawes Fretzin Clinical Research Group, LLC	Indianapolis	Indiana	46250	Recruiting
Kindred Hair and Skin Center	Marriottsville	Maryland	21104	Not yet recruiting
Michigan Dermatology Institute	Waterford	Michigan	48328	Recruiting
Ear, Nose & Throat Consultants, LLC	Omaha	Nebraska	68144	Recruiting
Skin Specialists, PC dba Schlessinger MD	Omaha	Nebraska	68144	Recruiting
University of New Mexico Health Sciences Center	Albuquerque	New Mexico	87102	Recruiting
University of New Mexico-IDS Pharmacy	Albuquerque	New Mexico	87106	Recruiting
Northwest Dermatology Institute	Portland	Oregon	97210	Recruiting
Penn State Health Milton S. Hershey Medical Center	Hershey	Pennsylvania	17033	Recruiting
Medical University of South Carolina - South Carolina Translational Research Nexus Clinic	Charleston	South Carolina	29425	Recruiting
Dell Children's Medical Center	Austin	Texas	78723	Not yet recruiting
Driscoll Children's Hospital	Corpus Christi	Texas	78411	Recruiting
3A Research	El Paso	Texas	79902	Recruiting
Austin Institute for Clinical Research	Pflugerville	Texas	78660	Recruiting
Texas Dermatology and Laser Specialists	San Antonio	Texas	78218	Recruiting
Children's Wisconsin	Milwaukee	Wisconsin	53226	Not yet recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07029828, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 15, 2026 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07029828 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →